A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control

被引:145
作者
Li, LM
Liao, J
Ruland, J
Mak, TW
Cohen, SN [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA
[2] Clontech Labs Inc, Palo Alto, CA 94303 USA
[3] Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada
[4] Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada
[5] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada
[6] Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada
关键词
tumorigenesis; ubiquitination; proteolysis;
D O I
10.1073/pnas.98.4.1619
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The p53 tumor suppressor protein and the MDM2 oncoprotein form a feedback-control loop that up-regulates cellular MDM2 production, blocks p53 activity, and promotes p53 decay, tsg101 was discovered as a gene whose deficiency results in neoplastic transformation of NIH 3T3 cells and the ability to generate metastatic tumors in nude mice. Its protein product contains a domain, Ubc, characteristic of the catalytic domain of ubiquitin conjugase (E2) enzymes but lacking an active-site cysteine crucial for ubiquitin conjugase activity. Here we report that TSG101 participates with MDM2 in an autoregulatory loop that modulates the cellular levels of both proteins, and also of p53, by affecting protein decay, We show that the Ubc domain of TSG101 interferes with ubiquitination of MDM2, that TSG101 inhibits MDM2 decay and elevates its steady-state level, and that these events are associated with down-regulation of p53 protein. Conversely, pulse-chase and Western blot experiments in wild-type and mutant fibroblasts indicate that elevation of MDM2 by overexpression of wild-type p53, by amplification of the endogenous MDM2 gene, or by transfection of MDM2-expressing constructs promotes TSG101 loss, which we show occurs by 26S proteasome-dependent decay. Our results identify TSG101 as both a regulator of, and target of, MDM2/p53 circuitry.
引用
收藏
页码:1619 / 1624
页数:6
相关论文
共 39 条
[21]  
LUNA RMD, 1995, NATURE, V378, P203
[22]  
McMasters KM, 1996, ONCOGENE, V13, P1731
[23]  
OLSON DC, 1993, ONCOGENE, V8, P2353
[24]   Regulation of the p53 tumor suppressor protein [J].
Oren, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (51) :36031-36034
[25]  
Ponting CP, 1997, J MOL MED-JMM, V75, P467
[26]   Signaling to p53: Breaking the MDM2-p53 circuit [J].
Prives, C .
CELL, 1998, 95 (01) :5-8
[27]   Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein [J].
Roth, J ;
Dobbelstein, M ;
Freedman, DA ;
Shenk, T ;
Levine, AJ .
EMBO JOURNAL, 1998, 17 (02) :554-564
[28]   p53 Accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101 [J].
Ruland, J ;
Sirard, C ;
Elia, A ;
MacPherson, D ;
Wakeham, A ;
Li, LM ;
de la Pompa, JL ;
Cohen, SN ;
Mak, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1859-1864
[29]   The ARF/p53 pathway [J].
Sherr, CJ ;
Weber, JD .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2000, 10 (01) :94-99
[30]  
Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO